MESO · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $2.0B · 81 employees
401
SEC Filings
$15.48
Close 2026-09-24
81
Employees
Business Summary
Mesoblast Limited is an Australian biotechnology company specializing in allogeneic cellular medicines for inflammatory diseases. Its first FDA-approved product, Ryoncil (remestemcel-L), treats steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients aged 2 months and older in the United States, launched in March 2025. Additional pipeline candidates include MPC-150-IM for chronic heart failure, MPC-06-ID for chronic low back pain, and MPC-300-IV for inflammatory conditions.
Look up MESO using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on MESO, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/MESO (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.